Clinical trial
STEP 3: why the behavioral intervention matters
Intensive behavioral support is part of the context when interpreting this weight-management study.
Read the study note ↗THE RESEARCH LIBRARY
Read the research.
Keep the context.
190 source-linked study notes. Explore the design, findings and limits behind the headline.
190 study notes Page 11 of 16
Clinical trial
STEP 4: the run-in period changes who enters the comparison
A randomized-withdrawal design studied continued treatment after an initial response and tolerability period.
Read the study note ↗Clinical trial
SURPASS-1: tirzepatide monotherapy in a defined diabetes population
This placebo-controlled trial investigated glucose control without background injectable diabetes therapy.
Read the study note ↗Clinical trial
SURPASS-2: reading a head-to-head diabetes trial
A head-to-head comparison needs its trial population, comparator and endpoint kept in view.
Read the study note ↗Clinical trial
SURPASS-3: comparing tirzepatide with titrated insulin degludec
An open-label trial examined two treatment strategies on background oral therapy.
Read the study note ↗Clinical trial
SURPASS-4: glucose outcomes and cardiovascular safety are different questions
The active-comparator trial enrolled adults with diabetes and increased cardiovascular risk.
Read the study note ↗Clinical trial
TAZPOWER: separating the randomized result from the open-label extension
The small Barth-syndrome trial did not meet its primary endpoints in the randomized phase.
Read the study note ↗Clinical trial
Topical and oral glutathione: a small formulation comparison
A small blinded study combined oral group allocation with topical treatment on facial sides and repeated color measurements.
Read the study note ↗Analytical study
Carrier-peptide delivery: stability versus complex formation
A carrier peptide was combined with insulin or a parathyroid-hormone fragment under different conditions in cell and animal models.
Read the study note ↗Clinical trial
GROW: oral glutathione did not improve the investigated growth outcomes
The pediatric trial provides a negative result that should remain part of the evidence record.
Read the study note ↗Analytical study
Plasma peptide measurements: collection tubes and storage are part of the assay
Chemically diverse quorum-sensing peptides were added to blood and evaluated across collection systems, handling conditions and storage periods.
Read the study note ↗Clinical trial
PROGRESS-HF: a neutral ventricular-volume endpoint
A phase 2 heart-failure trial found no significant improvement in its primary imaging outcome.
Read the study note ↗